Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

By The Northwire Desk — AI Analysis Jun 30, 2026 · 19:00 ONCO · 0.79 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Onco-Innovations Limited executed a term sheet for a non-brokered private placement with a notional subscription amount of approximately CAD$5,000,000.
  • The company is abandoning its previously announced Listed Issuer Financing Exemption (LIFE) offering filed on June 19, 2026, in favor of a complex "Sharing Agreement" structure.
  • The offering consists of 6,764,070 units at a notional price of CAD$0.7392 per unit, comprising common shares and warrants.
  • Securities are delivered into escrow and released to investors upon closing, meaning immediate dilution occurs.
  • No immediate cash proceeds are available to the company. Economic interest is determined via 18 monthly settlement tranches based on the monthly VWAP relative to a benchmark price of CAD$0.9691.
  • If the settlement price exceeds the benchmark, the company receives >100% of the monthly amount; if below, it receives <100%. There is no increase in shares issued if the price declines.
  • Subscription is to be satisfied in cash or via a portfolio of UK government bonds at market value, with investors assuming market/FX risk.
  • A corporate finance fee of CAD$400,000 is payable in cash or 541,126 Units at the company's election.
  • Proceeds are designated for advancing the ONC010 program, SynoGraph™ platform development, and general working capital.
  • Concurrently, the company announced the initiation of polymer process development and analytical characterization for ONC010 with Nanosoft Polymers to support future GMP manufacturing.
Material Impact
  • The financing structure is highly atypical for a preclinical-stage biotechnology company. By issuing shares immediately but deferring cash settlement over 18 months, the company provides zero near-term liquidity to address its existing cash crunch.
  • The performance-based settlement mechanism ties future cash inflows directly to stock price appreciation. Given the company's lack of revenue and preclinical status, achieving a sustained VWAP above the CAD$0.9691 benchmark is uncertain.
  • The structure is inherently dilutive upon closing due to immediate share issuance, while offering asymmetric downside risk to the company's cash runway if the stock trades below the benchmark.
  • The CAD$400,000 corporate finance fee further erodes the net capital efficiency of the transaction.
  • The concurrent R&D update regarding polymer process development is a standard IND-enabling milestone and does not offset the financing's structural drawbacks.
ONCO · Price
Company Overview
  • Onco-Innovations Limited is a preclinical-stage oncology company developing ONC010, a nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor targeting solid tumors.
  • The company operates a wholly-owned subsidiary, Inka Health Corp., which is advancing the SynoGraph™ AI-driven precision oncology platform for real-world evidence generation and external control arms.
  • Key development partners include Dalton Pharma Services (manufacturing), Nucro-Technics (preclinical/toxicology), Avance Clinical (clinical start-up), and strategic collaborators such as AstraZeneca and OneMedNet.
  • The company holds an exclusive worldwide license to patented PNKP inhibitor technology and is focused on transitioning from preclinical research to first-in-human clinical trials.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 25, 2026 · 08:30

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property Jun 19, 2026 · 19:00

Onco-Innovations Announces Non-Brokered LIFE Offering

Financings